Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Timothy Booker

Physician Assistant Little Rock, AR Physician Assistant

NPI 1538494091 CMS profile 10512631

9601 Baptist Health Dr, Suite 800, Little Rock, AR 72205

Open in the dashboard

General payments

$12,618

739 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Timothy Booker of Little Rock, AR is reported in the CMS Open Payments database as having received $12,618 across 739 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,934 100
2024 General $2,598 135
2023 General $2,720 161
2022 General $2,879 182
2021 General $2,487 161

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Timothy Booker
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Timothy Booker were reported at $1,934. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Timothy Booker Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $2,487 $132 $37–$438 $132
2022 $2,879 $155 $48–$522 $149
2023 $2,720 $167 $52–$557 $160
2024 $2,598 $178 $55–$600 $164
2025 $1,934 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $2,182 123 payments
  2. Novartis Pharmaceuticals Corporation $1,650 88 payments
  3. SK Life Science, Inc. $843 46 payments
  4. UCB, Inc. $834 54 payments
  5. Pfizer Inc. $732 50 payments
  6. Neurocrine Biosciences, Inc. $582 39 payments
  7. Amgen Inc. $512 24 payments
  8. Eisai Inc. $432 26 payments
  9. US WorldMeds, LLC $407 19 payments
  10. Biohaven Pharmaceuticals, Inc. $398 29 payments
  11. Other $4,046 241 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $12,506 738 payments
  2. Education $111 1 payment
Products named General payments · program years 2021–2025
  1. QULIPTA $1,395 71 payments
  2. KESIMPTA Neurology $1,180 60 payments
  3. UBRELVY $804 51 payments
  4. Briviact $720 48 payments
  5. NURTEC ODT Pain $710 49 payments
  6. ZAVZPRET $667 45 payments
  7. NURTEC ODT Primary Care $605 54 payments
  8. INGREZZA $468 30 payments
  9. AIMOVIG $446 21 payments
  10. KESIMPTA Neuroscience $388 24 payments
  11. Other $7,270 422 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 39 drugs

Part D claims

2,300

Median for Physician Assistant: 241

Drug cost

$643,013

Median for Physician Assistant: $4,110

Branded share of claims

34.3%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Emgality Pen Galcanezumab-Gnlm Brand 133 $122,116
Rytary Carbidopa/Levodopa Brand 90 $111,205
Ubrelvy Ubrogepant Brand 60 $77,587
Teriflunomide Generic 12 $74,747
Nurtec Odt Rimegepant Sulfate Brand 52 $71,146
Nuplazid Pimavanserin Tartrate Brand 12 $56,907
Briviact Brivaracetam Brand 24 $36,369
Fycompa Perampanel Brand 20 $24,351
Aimovig Autoinjector Erenumab-Aooe Brand 25 $18,568
Dalfampridine Er Dalfampridine Brand 22 $14,593

The 10 drugs with the highest cost, of 39 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 7 billing codes

Paid by Medicare

$37,294

Medicare's payments for the services billed

Medicare patients

408

Average age 72

Services billed

659

220 women, 188 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 54%
Ischemic heart disease 44%
Depression 42%
Chronic kidney disease 41%
Diabetes 35%
Heart failure 31%
Atrial fibrillation 27%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 34 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
QULIPTA
  • AbbVie, Inc. $424
$424 — —
KESIMPTA
  • Novartis Pharmaceuticals Corporation $408
$408 — —
NUPLAZID
  • ACADIA Pharmaceuticals Inc $151
$151 12 —
Gocovri
  • US WorldMeds, LLC $114
$114 — —
Briviact
  • UCB, Inc. $111
$111 24 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 34 with Patron

Records

739 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Arkansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record